U-46619
博飞美科提供的所有产品仅用于科研等非医疗用途，非药品不可食用，不可用于人体或动物的临床诊断和治疗,我们不为个人提供产品及服务。如您需要产品COA等资料，可至下方“质量控制”中下载
PA92868
PERFEMIKER
56985-40-1
C21H34O4
350.49
*注意事项:下单时请联系销售核实产品价格及货期，避免后续产生不便，感谢支持!
| 产品名称： |
U-46619 |
| 中文别名： |
9,11-二脱氧基-9Α,11Α-亚甲基环氧前列腺素 F2Α溶液;9,11-二脱氧基-9alpha,11alpha-亚甲基环氧前列腺素F2Α溶液（醋酸甲酯溶液） |
| 英文名称： |
U-46619 |
| 英文别名： |
9,11-Dideoxy-11α,9α-epoxymethanoprostaglandin F2α;9,11-DIDEOXY-9ALPHA,11ALPHA-METHANO-EPOXY PROSTAGLANDIN F2ALPHA;U 46619;U-46619;U 46619,(5Z)-7-[(1R,4S,5S,6R)-6-[(1E,3S)-3-Hydroxy-1-octenyl]-2-oxabicyclo[2.2.1]hept-5-yl]-5-heptenoicacid;U46619 |
| 品牌： |
PERFEMIKER |
| CAS号： |
56985-40-1 |
| 分子式： |
C21H34O4 |
| 分子量： |
350.49 |
| 纯度： |
98%, 10 mg/mL in methyl acetate |
| 详细描述： |
博飞美科的U-46619,98%为抑制剂,产品稳定,定制速度快,极大地方便了广大科研客户的使用需求。产品包装为1mg。查询关键词:抑制剂，56985-40-1，U-46619,98%，U-46619，博飞美科，Perfemiker，上海，厂家直销。 |
沪公网安备31011402010658号 
C(%5bH%5d)(%5bH%5d)%5bC%40%40%5d(C(%5bH%5d)(%5bH%5d)%5bH%5d)(%5bC%40%5d(%5bH%5d)(%5bC%40%5d(%5bH%5d)(C(%5bH%5d)(%5bH%5d)%5bH%5d)O1)OC(C(%5bH%5d)(%5bH%5d)%5bH%5d)%3dO)O%5bH%5d)%5bC%40%40%5d1(%5bH%5d)%5bC%40%40%5d(%5bH%5d)(%5bC%40%40%5d(%5bH%5d)(C(%5bH%5d)(%5bH%5d)%5bH%5d)O%5bC%40%5d(%5bH%5d)(C1(%5bH%5d)%5bH%5d)O%5bC%40%40%5d1(%5bH%5d)%5bC%40%40%5d(%5bH%5d)(%5bC%40%40%5d(%5bH%5d)(C(%5bH%5d)(%5bH%5d)%5bH%5d)O%5bC%40%5d(%5bH%5d)(C1(%5bH%5d)%5bH%5d)O%5bC%40%5d1(%5bH%5d)C(C2C(%3dC3C(%3dC(C(%5bH%5d)(%5bH%5d)%5bH%5d)C(%3dC(%5bH%5d)C3%3dC(%5bH%5d)C%3d2C(%5bH%5d)(%5bH%5d)%5bC%40%40%5d1(%5bH%5d)%5bC%40%40%5d(%5bH%5d)(C(%5bC%40%5d(%5bH%5d)(%5bC%40%40%5d(%5bH%5d)(C(%5bH%5d)(%5bH%5d)%5bH%5d)O%5bH%5d)O%5bH%5d)%3dO)OC(%5bH%5d)(%5bH%5d)%5bH%5d)O%5bC%40%40%5d1(%5bH%5d)C(%5bH%5d)(%5bH%5d)%5bC%40%5d(%5bH%5d)(%5bC%40%5d(%5bH%5d)(%5bC%40%40%5d(%5bH%5d)(C(%5bH%5d)(%5bH%5d)%5bH%5d)O1)OC(C(%5bH%5d)(%5bH%5d)%5bH%5d)%3dO)O%5bC%40%5d1(%5bH%5d)C(%5bH%5d)(%5bH%5d)%5bC%40%5d(%5bH%5d)(%5bC%40%5d(%5bH%5d)(%5bC%40%40%5d(%5bH%5d)(C(%5bH%5d)(%5bH%5d)%5bH%5d)O1)OC(%5bH%5d)(%5bH%5d)%5bH%5d)O%5bH%5d)O%5bH%5d)O%5bH%5d)%3dO)O%5bH%5d)O%5bH%5d)
C%3d2)F)%3dO)%5bC%40H%5d1C1C%3dNC%3dCC%3d1)%3dO)(F)F)
%3dO)C(COC(CCCC%2fC%3dC%5cC%2fC%3dC%5cC%2fC%3dC%5cCCCCC)%3dO)COC(CCCC%2fC%3dC%5cC%2fC%3dC%5cC%2fC%3dC%5cCCCCC)%3dO)
O)O)C%2fC%3dC%5cCCC(%3dO)OC)